Inhibitory effect of epidermal growth factor on resveratrol-induced apoptosis in prostate cancer cells is mediated by protien kinase C-α

Molecular Cancer Therapeutics

Volumn 3, Issue 11, 2004, Pages 1355-1363

  Shih, Ai ^a   Zhang, Shenli ^b   Cao, H James ^b   Boswell, Sarah ^b   Wu, Yun Hsuan ^b   Tang, Heng Yuan ^a   Lennartz, Michelle R ^c   Davis, Faith B ^b   Davis, Paul J ^a,b,d   Lin, Hung Yun ^a  

^a STRATTON VA MEDICAL CENTER   (United States)

^b ORDWAY RESEARCH INSTITUTE   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

^d WADSWORTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; MIDOSTAURIN; MITOGEN ACTIVATED PROTEIN KINASE; PHORBOL 13 ACETATE 12 MYRISTATE; PHORBOL ESTER; PROTEIN C FOS; PROTEIN C JUN; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; PROTEIN KINASE C GAMMA; PROTEIN P53; RESVERATROL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; DRUG ANTAGONISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; ENZYME ACTIVATION; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN KINASE C; PROTEIN KINASE C-ALPHA; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; SIGNAL TRANSDUCTION; STILBENES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 9444240465     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997;275: 218-20.
2. Fremont L. Biological effects of resveratrol. Life Sci 2000;66:663-73.
3. Shih A, Davis FB, Lin H-Y, Davis PJ. Resveratrol induces apoptosis in thyroid cancer cell lines via a mitogen-activated protein kinase- and p53-dependent mechanism. J Clin Endocrinol Metab 2002;87:1223-32.
4. Lin H-Y, Shih A, Davis FB, et al. Resveratrol-induced serine phosphorylation of p53 causes apoptosis in a mutant p53 prostate cell line. J Urol 2002;168:748-55.
5. Lin H-Y, Shih A, Davis FB, Davis PJ. Thyroid hormone promotes phosphorylation of STAT3 and potentiates the action of EGF in cultured cells. Biochem J 1999;338:427-32.
6. Ng J, Cantrell D. STAT3 is a serine kinase target in T lymphocytes. Interleukin 2 and T cell antigen receptor signals converge upon serine 727. J Biol Chem 1997;272:24542-9.
7. Putz T, Culig Z, Eder IE, et al. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res 1999;59:227-33.
8. Liu XH, Wiley HS, Meikle AW. Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-α (TGF-α) and epidermal growth factor (EGF) /TGF-α receptor. J Clin Endocrinol Metab 1993;77:1472-8.
9. Culig Z, Hobisch A, Cronauer MV, et al. Regulation of prostatic growth and function by peptide growth factors. Prostate 1997;28:392-405.
10. Seth D, Shaw K, Jazayeri J, Leedman PJ. Complete post-transcriptional regulation of EGF-receptor expression by EGF and TGF-α in human prostate cancer cells. Br J Cancer 1999;80:657-69.
11. Carruba G, Leake RE, Rinaldi F, et al. Steroid-growth factor interaction in human prostate cancer. 1. Short-term effects of transforming growth factors on growth of human prostate cancer cells. Steroids 1994;59: 412-20.
12. Jones HE, Barrow D, Dutkowski CM, et al. Effect of an EGF-R selective tyrosine kinase inhibitor and an anti-androgen on LNCaP cells: identification of divergent growth regulatory pathways. Prostate 2001;49: 38-47.
13. Khazaie K, Schirrmacher V, Lichtner RB. EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev 1993;12:255-74.
14. Wilding G, Valverius E, Knabbe C, Gelman EP. Role of transforming growth factor-α in human prostate cancer cell growth. Prostate 1989;15: 1-12.
15. Connolly JM, Rose DP. Autocrine regulation of DU145 prostate cancer cell growth by epidermal growth factor-related polypeptides. Prostate 1991;19:173-80.
16. Kuwajerwala N, Cifuentes E, Gautam S, Menon M, Barrack ER, Reddy GP. Resveratrol induces prostate cancer cell entry into S phase and inhibits DNA synthesis. Cancer Res 2002;62:2488-92.
17. Shih A, Lin H-Y, Davis FB, Davis PJ. Thyroid hormone promotes serine phosphorylation of p53 by mitogen-activated protein kinase. Biochemistry 2001;40:2870-8.
18. Lin H-Y, Zhang S, West BL, et al. Identification of the putative MAP kinase docking site in the thyroid hormone receptor-β1 DNA-binding domain: functional consequences of mutations at the docking site. Biochemistry 2003;42:7571-9.
19. Davis PJ, Shih A, Lin HY, et al. Thyroxine promotes association of mitogen-activated protein kinase and nuclear thyroid hormone receptor (TR) and causes serine phosphorylation of TR. J Biol Chem 2000;275: 38032-9.
20. Lin H-Y, Martino LJ, Wilcox BD, Davis FB, Gordinier JK, Davis PJ. Potentiation by thyroid hormone of human interferon-γ-induced HLA-DR expression. J Immunol 1998;161:843-9.
21. Irving J, Feng J, Wistrom C, Pikaart M, Villeponteau B. An altered repertoire of fos/jun (AP-1) at the onset of replicative senescence. Exp Cell Res 1992;202:161-6.
22. Joseph TW, Moll UT. Analysis of nuclear and cytoplasmic degradation of p53 in cell after stress. Methods Mol Biol 2003;234:211-7.
23. Li M, Brooks CL, Wu-Bear F, Chen D, Bear R, Gu W. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science 2003; 302:1972-5.
24. Lin H-Y, Davis FB, Gordinier JK, Martino LJ, Davis PJ. Thyroid hormone induces activation of mitogen-activated protein kinase in cultured cells. Am J Physiol 1999;276:C1014-24.
25. Lin H-Y, Thacore HR, Davis FB, Martino LJ, Davis PJ. Potentiation by thyroxine of interferon-γ-induced HLA-DR expression is protein kinase A- and C-dependent. J Interferon Cytokine Res 1996;16:17-24.
26. Djakiew D. Dysregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate 2000;42:150-60.
27. Shmueli A, Oren M. Regulation of p53 by Mdm2: fate is in the numbers. Mol Cell 2004;13:4-5.
28. Sengupta S, Wasylyk B. Ligand-dependent interaction of the glucocorticoid receptor with p53 enhances their degradation by Hdm2. Genes Dev 2001;15:2367-80.
29. Qi J-S, Yuan Y, Desai-Yajnik V, Samuels HH. Regulation of the mdm2 oncogene by thyroid hormone receptor. Mol Cell Biol 1999;19:864-72.
30. Zhou W, Janulis L, Park II, Lee C. A novel anti-proliferative property of clusterin in prostate cancer cells. Life Sci 2002;72:11-21.
31. Moretti RM, Marelli MM, Dondi D, et al. Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU145. J Clin Endocrinol Metab 1996;8:3930-7.
32. Elkeles A, Juven-Gershon T, Israeli D, Wilder S, Zalcenstein A, Oren M. The c-fos proto-oncogene is a target for transactivation by the p53 tumor suppressor. Mol Cell Biol 1999; 19:2594-600.
33. Montagnani Marelli M, Moretti RM, Dondi D, Limonta P, Motta M. Effects of LHRH agonists on the growth of human prostatic tumor cells: in vitro and in vivo studies. Arch Ital Urol Androl 1997;69:257-63.
34. Karin M, Liu Z, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 1997;9:240-6.
35. Sharma SC, Richards JS. Regulation of AP1 (Jun/Fos) factor expression and activation in ovarian granulosa cells. Relation of JunD and Fra2 to terminal differentiation. J Biol Chem 2000;275:33718-28.
36. Chen DB, Davis JS. Epidermal growth factor induces c-fos and c-jun mRNA via Raf-1/MEK1/ERK-dependent and -independent pathways in bovine luteal cells. Mol Cell Endocrinol 2003;200:141-54.
37. McClellan M, Kievit P, Auersperg N, Rodland K. Regulation of proliferation and apoptosis by epidermal growth factor and protein kinase C in human ovarian surface epithelial cells. Exp Cell Res 1999;246:471-9.
38. Hafezi F, Steinbach JP, Marti A, et al. The absence of c-fos prevents light-induced apoptotic cell death of photoreceptors in retinal degeneration in vivo. Nat Med 1997; 3:346-9.
39. Smeyne RJ, Vendrell M, Hayward M, et al. Continuous c-fos expression precedes programmed cell death in vivo. Nature 1993;363:166-9.
40. Slater SJ, Seiz JL, Cook AC, et al. Inhibition of protein kinase C by resveratrol. Biochim Biophys Acta 2003;1637:59-69.
41. Subbaramaiah K, Chung WJ, Michaluart P, et al. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem 1998;273:21875-82.
42. Garcia-Garcia J, Micol V, de Godos A, Gomez-Fernandez JC. The cancer chemopreventive agent resveratrol is incorporated into model membranes and inhibits protein kinase C-α-activity. Arch Biochem Biophys 1999;372:382-8.
43. Fujii T, Garcia-Bermejo ML, Bernabo JL, et al. Involvement of protein kinase Cδ (PKCδ) in phorbol ester-induced apoptosis in LNCaP prostate cancer cells. Lack of proteolytic cleavage of PKCδ. J Biol Chem 2000;275: 7574-82.
44. Isaacs WB, Carter BS, Ewing CM. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 1991;61:4716-20.
45. Saito Y, Hojo Y, Tanimoto T, Abe J, Berk BC. Protein kinase C-α and protein kinase C-E are required for Grb2-associated binder-1 tyrosine phosphorylation in response to platelet-derived growth factor. J Biol Chem 2002;277:23216-22.
46. Barnard D, Diaz B, Clawson D, Marshall M. Oncogenes, growth factors and phorbol esters regulate Raf-1 through common mechanisms. Oncogene 1998;17:1539-47.